Annovis Bio Stock Performance
| ANVS Stock | USD 1.83 0.05 2.81% |
The firm shows a Beta (market volatility) of 1.51, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Annovis Bio will likely underperform. At this point, Annovis Bio has a negative expected return of -1.23%. Please make sure to confirm Annovis Bio's standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Annovis Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Annovis Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Disposition of 1068054 shares by Maria Maccecchini of Annovis Bio subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Hagopian Henry Iii of 7672 shares of Annovis Bio subject to Rule 16b-3 | 01/16/2025 |
3 | Annovis Bio, Inc. Announces Pricing of 21 Million Public Offering | 02/03/2025 |
4 | Annovis Bio, Inc. Announces Closing of 21 Million Public Offering | 02/04/2025 |
5 | Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimers Disease | 02/05/2025 |
6 | Annovis to Present at Oppenheimers 35th Annual Healthcare Life Sciences Conference | 02/07/2025 |
7 | Annovis Bio stock hits 52-week low at 2.59 amid sharp decline - Investing.com | 02/11/2025 |
8 | Annovis to Host Patients Live Forum on February 27, 2025 | 02/19/2025 |
9 | Acquisition by Michael Hoffman of 7142 shares of Annovis Bio at 0.25 subject to Rule 16b-3 | 02/28/2025 |
10 | Acquisition by Jeffrey McGroarty of 165199 shares of Annovis Bio at 20.97 subject to Rule 16b-3 | 03/07/2025 |
11 | Annovis Joins Experts at Drug Development Summit to Redefine Parkinsons Treatment | 03/11/2025 |
12 | Greenwich Wealth Management LLC Increases Position in Annovis Bio, Inc. | 03/17/2025 |
| Begin Period Cash Flow | 28.4 M |
Annovis |
Annovis Bio Relative Risk vs. Return Landscape
If you would invest 440.00 in Annovis Bio on December 19, 2024 and sell it today you would lose (257.00) from holding Annovis Bio or give up 58.41% of portfolio value over 90 days. Annovis Bio is currently does not generate positive expected returns and assumes 6.3207% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Annovis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Annovis Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Annovis Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Annovis Bio, and traders can use it to determine the average amount a Annovis Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1945
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANVS |
Estimated Market Risk
| 6.32 actual daily | 56 56% of assets are less volatile |
Expected Return
| -1.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Annovis Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Annovis Bio by adding Annovis Bio to a well-diversified portfolio.
Annovis Bio Fundamentals Growth
Annovis Stock prices reflect investors' perceptions of the future prospects and financial health of Annovis Bio, and Annovis Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Annovis Stock performance.
| Return On Equity | -5.97 | ||||
| Return On Asset | -1.55 | ||||
| Current Valuation | 24.97 M | ||||
| Shares Outstanding | 19.49 M | ||||
| Price To Earning | (0.43) X | ||||
| Price To Book | 5.32 X | ||||
| EBITDA | (45.04 M) | ||||
| Net Income | (56.2 M) | ||||
| Cash And Equivalents | 35.97 M | ||||
| Cash Per Share | 4.41 X | ||||
| Total Debt | 17.96 M | ||||
| Debt To Equity | (0.31) % | ||||
| Current Ratio | 28.11 X | ||||
| Book Value Per Share | 0.53 X | ||||
| Cash Flow From Operations | (39.97 M) | ||||
| Earnings Per Share | (4.22) X | ||||
| Market Capitalization | 34.69 M | ||||
| Total Asset | 10.21 M | ||||
| Retained Earnings | (110.26 M) | ||||
| Working Capital | 5.93 M | ||||
| Current Asset | 986 K | ||||
| Current Liabilities | 216 K | ||||
About Annovis Bio Performance
Assessing Annovis Bio's fundamental ratios provides investors with valuable insights into Annovis Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Annovis Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.96) | (5.20) | |
| Return On Capital Employed | (8.73) | (8.30) | |
| Return On Assets | (4.96) | (5.20) | |
| Return On Equity | 6.53 | 6.85 |
Things to note about Annovis Bio performance evaluation
Checking the ongoing alerts about Annovis Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Annovis Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Annovis Bio generated a negative expected return over the last 90 days | |
| Annovis Bio has high historical volatility and very poor performance | |
| Annovis Bio may become a speculative penny stock | |
| Annovis Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (56.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Annovis Bio currently holds about 35.97 M in cash with (39.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Annovis Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Greenwich Wealth Management LLC Increases Position in Annovis Bio, Inc. |
- Analyzing Annovis Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Annovis Bio's stock is overvalued or undervalued compared to its peers.
- Examining Annovis Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Annovis Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Annovis Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Annovis Bio's stock. These opinions can provide insight into Annovis Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.